Targeting specific tumor characteristics such as proliferation (chemotherapy, radiotherapy, and EGFR inhibitors) and network integration (e.g., ion channel modulators) can eliminate specific tumor populations and may induce differentiation to improve GBM treatment efficiency. Here, EGFR is linked to glioblastoma.